Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 20.99M | $56.0M | 29.03% | -- | 2026-06-30 |
| Sands Capital Alternatives, LLC | 3.72M | $9.0M | 5.14% | -- | 2026-06-30 |
| BlackRock, Inc. | 2.49M | $6.0M | 3.44% | +2.31M | 2026-06-30 |
| Alyeska Investment Group, L.P. | 2.45M | $6.0M | 3.39% | -- | 2026-06-30 |
| Franklin Resources Inc | 2.31M | $6.0M | 3.19% | -- | 2026-06-30 |
| ADAR1 Capital Management, LLC | 2.11M | $5.0M | 2.92% | -45.0K | 2026-06-30 |
| Vanguard Capital Management LLC | 1.67M | $4.0M | 2.31% | +165.8K | 2026-06-30 |
| Knollwood Investment Advisory, LLC | 1.63M | $4.0M | 2.25% | -- | 2026-06-30 |
| Geode Capital Management, LLC | 1.14M | $3.0M | 1.58% | +725.6K | 2026-06-30 |
| Ikarian Capital, LLC | 1.05M | $2.0M | 1.46% | -- | 2026-06-30 |
